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We report the ﬁrst case of an anaphylactic reaction to Reandron 1000 (depot testosterone undecanoate with a castor oil and benzyl
benzoatevehicle).Whileconsideredtohaveafavourablesafetyproﬁle,seriouscomplicationssuchasoilembolismandanaphylaxis
can occur. In our patient, skin testing identiﬁed benzyl benzoate to be the trigger, with no reaction to castor oil or testosterone
undecanoate components. As benzyl benzoate exists in multiple pharmaceuticals, foods, and cosmetics, individual components of
pharmaceuticals should be tested when investigating drug allergies. Doctors should be alert to the potential for serious reactions to
any of the components of Reandron 1000.
1.Introduction
In men requiring testosterone therapy, depot testosterone
undecanoate (TU) is a useful option. Compared to conven-
tional testosterone esters, depot TU maintains adequate tes-
t o s t e r o n el e v e l sw i t hl e s sf r e q u e n ti n j e c t i o n sa n dh a sb e t -
ter pharmacokinetics. Speciﬁcally, depot TU comparatively
achieves higher trough serum testosterone concentrations
without the wide variation between peak and trough levels
between doses [1]. TU was initially developed in the 1970s as
an oral testosterone replacement preparation, with a trans-
dermal patch available in the 1990s [1]. In China, a depot
TU preparation witha Chinese teaseed oil vehicle wasmanu-
facturedfor intramuscularuse and found to have a long half-
life of 21 days, longer than conventionally used testosterone
esters [2, 3] .D e p o tT Ui sc u r r e n t l ym a r k e t e dw i t hac a s t o r
oil and benzyl benzoate vehicle [4], as the castor oil aﬀords
an even longer half-life (33.9 days) than the original Chinese
depot preparation [2, 5].
Thelong-termoverallsafetyproﬁleofdepotTUhasbeen
generally favourable [6, 7]. Anaphylaxis to depot TU has not
been speciﬁcally reported although hypersensitivity is listed
as an uncommon adverse eﬀect in the manufacturer’s prod-
uctinformation[4].Hypersensitivityreactionshavenotbeen
described in cohorts who have used this preparation from 4
t o8y e a r s .
Here, we report the ﬁrst documented case of anaphylaxis
toReandron1000,adepotpreparationofTU.Thiscaseisno-
table for the fact that the responsible agent was not the main
active ingredient.
2. Case Presentation
A16-year-oldboywithprimaryhypogonadismduetobilate-
rallyabsenttestes,butotherwisewithoutremarkablemedical
history, was converted from monthly intramuscular injec-
tions of testosterone esters (Sustanon, Schering-Plough) to
depot testosterone undecanoate (Reandron 1000, Bayer) due
to debilitating ﬂuctuations in mood and energy levels. There
was signiﬁcant improvement in symptoms on the depot pre-
paration.
Within four minutes after his third dose was admin-
istered, he developed sweatiness, facial swelling, itching,
urticaria, and sensation of throat obstruction with chest2 Case Reports in Medicine
tightness. He was normotensive without tachycardia. He
was treated with intravenous promethazine and hydrocor-
tisone 250mg and observed in an emergency department.
Adrenaline (epinephrine) was not administered. The diﬀer-
ential diagnosis of oil embolism was not pursued in view of
the classical clinical features of anaphylaxis.
A skin prick test found deﬁnite reaction to Reandron
1000witha10 ×8mmwheal,butnoreactiontotestosterone
esters gel or saline solution control. Testing of the compo-
nents of Reandron 1000 found that non-skin-irritating con-
centrations of benzyl benzoate resulted in a 10 × 10mm
wheal and smaller peripheral lesions. Neither castor oil nor
TUinduced a response. His fatherwastested asa controland
did not react to any of the components.
Since discontinuation of Reandron 1000, the patient has
used topical testosterone ester gel and crystalline testosterone
pellets were implanted subcutaneously. There have been no
further episodes of anaphylaxis.
3. Discussion
We report a case of anaphylaxis to a depot preparation of TU
comprising three components. Testing of each component
identiﬁed benzyl benzoate as the likely trigger and demon-
strates the importance of testing every component when in-
vestigating and managing medication-related anaphylaxis.
Neither Reandron 1000 nor benzyl benzoate has been pre-
viously reported as a trigger for anaphylaxis.
Excipients are the components of pharmaceuticals apart
from the active substance. They fulﬁl a variety of diﬀerent
roles including colouring, ﬂavouring, and alteration of the
stability, solubility, durability, or permeability of the active
ingredient. These agents are capable of inducing severe ad-
verse drug reactions, particularly in the paediatric popula-
tion [8]. Immunologically mediated hypersensitivity reac-
tions can manifest as immediate (within 1 hour) onset of
urticaria, angioedema, or anaphylaxis. Alternatively, there
can be a delayed (>1 hour) onset of mostly cutaneous symp-
toms which, as in Stevens-Johnson syndrome, can still be
severe [9]. In Reandron 1000, the excipient agents are benzyl
benzoate and castor oil, while the active ingredient is TU.
Benzyl benzoate (chemical formula C14H12O2) is a colo-
urless oily liquid which is rapidly metabolised by the body
to benzoic acid and benzyl alcohol [10]. The agent is widely
used as an additive in many diﬀerent pharmaceutical and
nonpharmaceutical products for human consumption. For
instance, it is used as a preservative, a solvent in perfumes,
a ﬂavouring agent in foods and medications, and in insecti-
cides and insect repellents [10, 11]. In oil-based vehicles for
depot steroids, it lowers viscosity to improve ease of admin-
istration [12] and prevents crystallisation of steroids during
storage [10, 13]. In testosterone preparations, it is also found
in testosterone cypionate (Depo-Testosterone, Pharmacia)
but not testosterone esters (Sustanon) or testosterone gel.
In its role as a topical insecticide for scabies, benzyl ben-
zoate is applied in a diluted solution with a concentration
between 10% and 25%. It is known to cause skin irritation
and contact dermatitis in this context, but hypersensitivity
reactions have not been recorded in existing studies. No
information is available as to whether or not benzyl benzoate
possesses the intrinsic ability to induce mast cell degranula-
tion.Databasesforadversereactionshavealsoidentiﬁedcon-
vulsions occurring with ingested benzyl benzoate [10, 14].
Although not previously reported, hypersensitivity reac-
tions to benzyl benzoate are unlikely to be isolated to our pa-
tient. Its presence in numerous consumer products raises the
possibility of underreporting due to lack of awareness and
failure to identify it as the trigger. Existing guidelines by the
British Society for Allergy and Clinical Immunology [15]
recommend skin prick testing if a compatible history of IgE-
mediated drug hypersensitivity exists. In our patient, signs
and symptoms of anaphylaxis to testosterone therapy and
the clinical need for ongoing testosterone therapy warranted
such investigation. Although intuitive and in common prac-
tice, there are no speciﬁc recommendations regarding testing
of individual components of pharmaceutical preparations in
either British or Australian [16] guidelines. In our patient,
discovery of a reaction to a single component of the depot
vehiclewillbetterguideselectionoftestosteronereplacement
therapies. It will also allow him to remain vigilant to benzyl-
benzoate-containing products.
Castoroilhasbeenusedasavehicleforsteroidhormones
for decades, prolonging their eﬀect compared to equivalent
aqueous suspensions by increasing storage in fatty depots in
the body [12]. While there have been no reports of anaphy-
laxis to castor oil, sudden onset of respiratory symptoms can
signify oil-related pulmonary microembolism after entry via
the lymphatic or venous system. This complication is rare
[17].
In this case, our patient received supportive care for ana-
phylaxis with antihistamines and glucocorticoids. The im-
mediate management of anaphylaxis is not guided by ran-
domised placebo-controlled trials which are unethical due to
the potential for rapid progression to fatality arising from
delay of treatment. The use of adrenaline (epinephrine) is
widespreadandrecommendedinmultipleguidelinesasﬁrst-
line therapy based upon results of uncontrolled studies [18].
However,recommendationsforuseofadjunctiveagentssuch
as antihistamines and glucocorticoids are more heterogene-
ous. The use of H1-antagonists as a ﬁrst-line agent is not
recommended, as they are of slow onset, fail to relieve bron-
chospasm or gastrointestinal symptoms, and have anticholi-
nergic eﬀects which can induce drowsiness and confuse the
clinical picture in a critically ill patient [19]. Similarly, gluco-
corticoids do not acutely relieve symptoms but prevent pro-
longed or biphasic symptoms of anaphylaxis [18]. These
agents are best used in conjunction with, rather than in place
of adrenaline.
4. Conclusion
Anaphylactic reactions can occur to the benzyl benzoate
component of depot preparations of testosterone undecan-
oate. It is potentially unrecognised or can be misdiagnosed
as oil embolism and underreported. Testing for reactions
to the individual components of pharmaceutical agents may
prevent inappropriate exclusion of all available preparations
of a particular agent if it is the vehicle rather than the activeCase Reports in Medicine 3
ingredient that is causative. Similarly, it will alert the patient
to risk of hypersensitivity to unrelated products which may
utilise the same agent. Doctors should remain aware of the
potential for serious reactions to testosterone replacement
therapies and should consider appropriate further investiga-
tion.
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